03 jul: 2nd UPDATE: BMC Agrees to Nominate 2 Elliott Board Candidates
03 jul: WSJ UPDATE: U.S. Auto Sales Climb in June, Surpassing Expectation..
03-07-2012 21:09:00

UPDATE: FDA Approves OraSure's Over-The-Counter Home HIV Test

Relateret indhold
03 apr - 
Verdens største virksomhed

--FDA approves first HIV test to be sold in retail stores

--Test will be available in October

--Home test appears to be not as accurate as tests by health professionals

(Adds company comments on test availability, pricing, in the third and fourth paragraphs.)

By Jennifer Corbett Dooren

WASHINGTON--The Food and Drug Administration Tuesday approved a home HIV test that will be sold in retail stores so people wouldn't have to go to a health facility to learn if they have the virus.

The test, made by OraSure Technologies Inc. (OSUR), has been available to health-care professionals. The test, called the OraQuick In-Home HIV test, uses a mouth swab to collect saliva. The swab is then inserted into a test tube where results are made available within a 20-to-40 minute time frame.

Company officials said the test will be available in October and sold at more than 30,000 retailers such as Wal-Mart Stores Inc. (WMT) and large grocery and drug-store chains including CVS Caremark Corp. (CVS), Rite Aid Corp. (RAD) and Walgreen Co. (WAG). The test will also be sold online.

OraSure said a price hasn't been established but it will be slightly higher than the $17.50 currently paid by health-care professionals, to fund additional labeling costs and a customer-support center.

The FDA said a positive result needs to be confirmed with a follow-up test in a health-care facility. The agency also said negative readings don't necessarily mean people aren't infected with HIV because the test might not be able to pick up infections within three months before testing.

Still, the agency said the test has the potential to identify large numbers of previously undetected HIV infections, especially if used by people unlikely to use standard screening methods.

About 1.2 million people in the U.S. are infected with HIV, and about 50,000 infections are diagnosed each year, a level that has been stable for a decade. Federal health officials have estimated that 20% of people with HIV don't realize they are infected and risk spreading the virus, which causes AIDS.

"Knowing your status is an important factor in the effort to prevent the spread of HIV," said Dr. Karen Midthun, director of FDA's Center for Biologics Evaluation and Research. "The availability of a home-use HIV test kit provides another option for individuals to get tested so that they can seek medical care, if appropriate."

However, there is one concern about the home test: Clinical testing has showed it doesn't appear to be as accurate as tests conducted by health professionals.

One measure of the test's accuracy in the home setting showed it had a sensitivity rate of 92%. The FDA said this means there would be one false negative test result for every 12 tests taken in HIV-infected individuals.

The FDA said one false positive result would be expected out of every 5,000 test results taken by uninfected individuals.

Write to Jennifer Corbett Dooren at jennifer.corbett@dowjones.com.

(END) Dow Jones Newswires

July 03, 2012 15:09 ET (19:09 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Novo: Analytikerne skruer op for forventningerne efter regnskab

03-03-2015 15:29:30
Analytikerne er i samlet flok blevet endnu mere positivt indstillet over for Novo Nordisks potentiale i de kommende år efter årsregnskabet for 2014 fra medicina..

Genmab/Jyske: Lægger ekstra 60 kr. til kursmålet

03-03-2015 13:09:35
Der var ikke meget nyt i Genmabs regnskab for fjerde kvartal, vurderer Jyske Bank, der dog alligevel løfter kursmålet for biotekaktien med 60 kr. til 570 efter ..

Aktier/åbning: C20 lidt ned trods stigning i Genmab

03-03-2015 09:22:04
Det danske aktiemarked startede tirsdag i et lille plus, men efter et kvarters handel har markedet taget en negativt drejning. Eliteindekset C20 Cap ligger ved ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo: Analytikerne skruer op for forventningerne efter regnskab
2
Eivind Kolding tror på godt afkast af NNIT - avis
3
Novo: Eksperter taler konkurrents nye insulinmiddel ned
4
Genmab/Jyske: Lægger ekstra 60 kr. til kursmålet
5
Genmab indregner milepæle fra Daratumumab-ansøgninger

Relaterede aktiekurser

Rite Aid Corp 8,10 -0,7% Fald i aktiekurs
Wal-Mart Stores Inc 83,37 -0,7% Fald i aktiekurs
CVS Health Corporation 103,45 -0,7% Fald i aktiekurs
OraSure Technologies Inc 7,18 -1,8% Fald i aktiekurs

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
4. marts 2015 03:48:49
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150225.2 - EUROWEB5 - 2015-03-04 03:48:49 - 2015-03-04 03:48:49 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x